Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Completed 4Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Conditions

Melanoma 273Carcinoma, Non-Small-Cell Lung 244Carcinoma, Renal Cell 143Neoplasm Metastasis 99Neoplasms 98Squamous Cell Carcinoma of Head and Neck 88Carcinoma, Hepatocellular 86Colorectal Neoplasms 81Lung Neoplasms 77Stomach Neoplasms 59Pancreatic Neoplasms 56Carcinoma, Transitional Cell 50Hodgkin Disease 47Urinary Bladder Neoplasms 42Head and Neck Neoplasms 42Breast Neoplasms 40Ovarian Neoplasms 37Triple Negative Breast Neoplasms 34Small Cell Lung Carcinoma 33Brain Neoplasms 33Sarcoma 32Glioblastoma 32Prostatic Neoplasms 31Kidney Neoplasms 29Recurrence 28Multiple Myeloma 25Esophageal Neoplasms 24Uveal Melanoma 23Skin Neoplasms 23Uterine Cervical Neoplasms 22

Interventions

Nivolumab 5Ipilimumab 3relatlimab 1daratumumab 1Fluorouracil 1Cisplatin 1BMS-986115 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Various Advanced Cancer × Nivolumab × Clear all
NCT03143153 2026-02-17

CheckMate 648

Bristol-Myers Squibb

Phase 3 Completed
970 enrolled 15 charts 1 FDA

Various Advanced Cancer

NCT02632409 2025-10-16

CheckMate 274

Bristol-Myers Squibb

Phase 3 Active not recruiting
709 enrolled 13 charts 1 FDA

Various Advanced Cancer

NCT02488759 2023-11-13

CheckMate358

Bristol-Myers Squibb

Phase 1/2 Completed
578 enrolled 19 charts

Various Advanced Cancer

NCT02387996 2022-11-01

A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer

Bristol-Myers Squibb

Phase 2 Completed
270 enrolled 14 charts

Various Advanced Cancer

NCT03130959 2022-08-09

CheckMate 908

Bristol-Myers Squibb

Phase 2 Completed
166 enrolled 33 charts

Various Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡